Current Project and Members
Meet the 2024 Team!
We are a team of nine students from diverse majors and backgrounds working to develop the Bacillus Lipase Integrated Secretion System (BLISS), a novel probiotic designed to treat Exocrine Pancreatic Insufficiency (EPI) as an alternative to existing porcine-derived treatments.
Our Project Abstract
Exocrine pancreatic insufficiency (EPI) affects an estimated 10-20% of the global population and leads to malnutrition. This chronic condition is closely linked to pancreatitis, cystic fibrosis, cancer, and diabetes. It is commonly treated with pancreatic enzyme replacement therapy (PERT) with an oral drug containing porcine pancreatic enzymes. However, the prohibitive cost of PERT, up to $4,840 for a 30-day supply, places a significant financial burden on patients already struggling with associated medical expenses. PERT is also a barrier for EPI patients who have religious or dietary restrictions that prevent consumption of porcine products. Additionally, ethical concerns have been raised by animal rights activists about the slaughter of pigs for their pancreas and the negative environmental impact of pig farms. To provide a pig-free treatment option, our team presents the Bacillus Lipase Integrated Secretion System (BLISS), a probiotic that releases synthetic pancreatic enzymes suitable for the human body. BLISS is a more accessible, cost-effective, and environmentally friendly solution than PERT. In the end, BLISS will transform EPI treatment, offering patients a solution that aligns with their values and turns symptom management into a truly blissful experience.
Read more about BLISS on our wiki!
Our Team